Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease

American Journal of Cardiology

Volumn 89, Issue 8, 2002, Pages 901-908

  Bickel, Christoph ^a,b   Rupprecht, Hans J ^a   Blankenberg, Stefan ^c   Espiniola Klein, Christine ^a   Schlitt, Axel ^a   Rippin, Gerd ^a   Hafner, Gerd ^a   Treude, Rainer ^b   Othman, Hisham ^b   Hofmann, Klaus Peter ^b   Meyer, Jürgen ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

^c Department of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR INFLAMMATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS;

EID: 0037090366     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02236-1     Document Type: Article

References (29)

1. Atherosclerosis - An inflammatory disease
2. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
3. Production of C-reactive protein and risk of coronary events in stable and unstable angina
4. Novel inflammatory markers of coronary risk: Theory versus practice
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
10. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease
11. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
12. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
13. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
14. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
15. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study
16. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population
17. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
18. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin
19. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
20. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
21. Statins do more than just lower cholesterol
22. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
23. Are there potential non-lipid-lowering uses of statins?
24. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
25. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
26. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
27. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
28. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
29. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease